Trial Profile
A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 20 Mar 2024
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gefitinib (Primary) ; Osimertinib (Primary) ; Ramucirumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms RELAY
- Sponsors Eli Lilly and Company
- 15 Mar 2024 Planned End Date changed from 16 Dec 2023 to 16 Dec 2024.
- 17 Jun 2023 Results assessing efficacy and tolerability findings for the Taiwanese participants, published in the Targeted Oncology.
- 01 Aug 2022 Results (n=441) assessing the exposure-response relationship of ramucirumab, published in the Cancer Chemotherapy and Pharmacology.